Heme oxygenase-1 (HO-1, encoded by the HMOX1 gene) is a 32 kDa inducible enzyme that catalyzes the rate-limiting step in heme degradation, converting heme into biliverdin, iron (Fe²⁺), and carbon monoxide (CO). Originally characterized for its role in erythrocyte turnover and iron recycling, HO-1 has emerged as a critical cytoprotective protein in the nervous system with profound implications for neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and others. [@schipper2019]
HO-1 belongs to the heme oxygenase family which includes two isoforms: the inducible HO-1 (HMOX1) and the constitutive HO-2 (HMOX2). While HO-2 is primarily expressed in the brain and testis, HO-1 is expressed at low levels under normal physiological conditions but can be dramatically induced by cellular stress, making it a central player in the cellular stress response. [@nath2019]
| Property |
Value |
| Protein Name |
Heme Oxygenase-1 (HO-1) |
| Gene Symbol |
HMOX1 |
| Chromosomal Location |
22q12.3 |
| NCBI Gene ID |
3162 |
| UniProt ID |
P09601 (HO1_HUMAN) |
| Molecular Weight |
32 kDa |
| Subcellular Location |
Endoplasmic reticulum, mitochondria |
| Inducers |
Heme, oxidative stress, cytokines, heat shock |
| Inhibitors |
SnPP, ZnPP, synthetic metalloporphyrins |
¶ Structure and Catalytic Mechanism
HO-1 is a homodimeric enzyme with each monomer consisting of:
- N-terminal transmembrane helix (residues 1-23): Anchors the protein to the endoplasmic reticulum membrane
- Heme binding pocket (residues 24-200): Contains the catalytic site where heme degradation occurs
- Proximal helix: Provides the iron ligand for heme binding
- Distal helix: Forms the substrate access channel
- C-terminal regulatory domain: Modulates enzyme activity and protein interactions
The crystal structure of HO-1 reveals a unique "sheltered" binding pocket where the heme molecule is sandwiched between two helical segments, with the catalytic Asp140 and His25 playing critical roles in the oxygenation reaction. [@alam2022]
The HO-1 catalyzed reaction proceeds in three steps:
- Heme oxygenation: Fe²⁺-heme + O₂ + NADPH + H₂O → biliverdin + Fe²⁺ + CO + NADP⁺ + H₂O
- Biliverdin reduction: Biliverdin + NADPH → bilirubin (via biliverdin reductase)
- Iron release: Ferrous iron (Fe²⁺) is either sequestered by ferritin or released
The reaction requires NADPH-cytochrome P450 reductase (CPR) as an electron donor, making HO-1 part of the microsomal monooxygenase system. Importantly, the products of heme catabolism—biliverdin/bilirubin, CO, and ferritin-bound iron—all possess biological activities relevant to neuroprotection. [@schipper2019]
Under normal physiological conditions, HO-1 is expressed at low levels in the brain but serves critical homeostatic functions:
Antioxidant Defense: HO-1 is a key component of the Nrf2-ARE antioxidant response pathway. The Nrf2 transcription factor translocates to the nucleus upon oxidative stress and binds to the antioxidant response element (ARE) in the HMOX1 promoter, dramatically upregulating HO-1 expression. This creates a feedback loop where oxidative stress induces HO-1, and the products of heme degradation (particularly biliverdin and bilirubin) provide antioxidant protection. [@alam2022]
Anti-inflammatory Activity: HO-1 exerts potent anti-inflammatory effects through multiple mechanisms:
- Inhibition of NF-κB signaling pathway
- Suppression of pro-inflammatory cytokine production (TNF-α, IL-1β, IL-6)
- Promotion of anti-inflammatory M2 microglial phenotype
- Modulation of T-cell responses
The CO produced by HO-1 activity acts as a signaling molecule that inhibits inflammatory responses through modulation of MAPK pathways and inhibition of NF-κB. [@barsoum2019]
Mitochondrial Protection: HO-1 localizes to mitochondria in neurons and astrocytes, where it:
- Maintains mitochondrial membrane potential
- Preserves electron transport chain function
- Prevents mitochondrial permeability transition
- Promotes mitophagy to remove damaged mitochondria
This mitochondrial localization is particularly relevant to neurodegenerative diseases, where mitochondrial dysfunction is a central pathogenic mechanism. [@chen2023]
Iron Homeostasis: By degrading heme and promoting ferritin expression, HO-1 plays a crucial role in maintaining iron balance in the brain. The induction of HO-1 leads to increased ferritin synthesis, which sequesters potentially toxic free iron, preventing iron-catalyzed oxidative damage. This is particularly important in brain regions susceptible to iron accumulation and neurodegeneration. [@kim2023]
In the normal brain, HO-1 expression varies by cell type:
- Neurons: Low basal expression, rapidly inducible under stress
- Astrocytes: Constitutive expression at moderate levels, strongly induced
- Microglia: Low basal expression, highly inducible by inflammatory stimuli
- Oligodendrocytes: Limited expression, increases in demyelinating conditions
- Endothelial cells: Expresses HO-1 at blood-brain barrier interfaces
The inducible nature of HO-1 makes it a sentinel of cellular stress across all neural cell types, positioning it as a potential therapeutic target in neurodegeneration. [@schipper2000]
Multiple studies have documented elevated HO-1 expression in Alzheimer's disease brains. Immunohistochemical analyses reveal:
- Increased HO-1 immunoreactivity in hippocampus, cortex, and amygdala
- Localization to neurons, astrocytes, and microglia surrounding amyloid plaques
- Correlation with disease severity
- Co-localization with hyperphosphorylated tau pathology
The upregulation of HO-1 in AD is interpreted as a compensatory neuroprotective response to oxidative stress, amyloid-beta (Aβ) toxicity, and neuroinflammation. However, chronic HO-1 induction may become maladaptive, contributing to disease progression. [@song2020]
Amyloid-beta Interaction: Aβ peptides directly induce HO-1 expression in neurons and glia through oxidative stress-dependent mechanisms. The HO-1 induction is part of a broader cellular stress response, but the enzyme's activity may influence Aβ metabolism:
- Biliverdin and bilirubin can inhibit Aβ aggregation in vitro
- CO signaling may modulate amyloid precursor protein (APP) processing
- HO-1-induced iron release could influence Aβ-induced oxidative stress
Oxidative Stress Modulation: AD brains exhibit severe oxidative damage to lipids, proteins, and DNA. HO-1 provides antioxidant protection through:
- Production of bilirubin, a potent lipid-soluble antioxidant
- Induction of ferritin, sequestering free iron
- CO-mediated inhibition of ROS-generating enzymes
Neuroinflammation: Chronic neuroinflammation is a hallmark of AD. HO-1 exerts anti-inflammatory effects that may be beneficial:
- Suppression of microglial activation
- Reduction in pro-inflammatory cytokine expression
- Promotion of anti-inflammatory phenotype
However, sustained HO-1 activity may also have negative consequences, including promotion of pro-oxidant iron release when ferritin induction is insufficient. [@peacock2023]
Polymorphisms in the HMOX1 gene have been associated with AD risk:
- (GT)n repeat polymorphisms: Affect HMOX1 transcriptional activity
- Promoter variants: Influence inducibility under stress
- Functional SNPs: May alter enzyme expression levels
Studies have reported inconsistent associations, likely due to population differences and gene-environment interactions. [@goetzl2020]
HO-1 represents a promising therapeutic target for AD:
- HO-1 inducers: Natural compounds (curcumin, sulforaphane) and pharmacological agents can upregulate HO-1 expression
- CO-releasing molecules: CO donors may provide neuroprotective effects without heme degradation
- Bilirubin analogs: Synthetic antioxidants based on biliverdin/bilirubin structures
- Gene therapy: AAV-mediated HO-1 delivery has shown promise in preclinical models
Parkinson's disease is characterized by progressive loss of dopaminergic neurons in the substantia nigra pars compacta and the presence of Lewy bodies containing alpha-synuclein. HO-1 is profoundly upregulated in PD brains:
- Markedly elevated HO-1 in substantia nigra neurons
- Co-localization with Lewy bodies
- Association with disease severity
- Correlation with dopaminergic neuron loss
The pattern of HO-1 induction in PD suggests it plays a complex role in disease pathogenesis—initially protective but potentially contributing to iron dysregulation and progression with chronic activation. [@lin2007]
Alpha-synuclein Aggregation: HO-1 expression is induced by alpha-synuclein aggregates:
- Protein aggregates activate cellular stress pathways
- Oxidative stress from aggregates triggers HO-1 induction
- HO-1 may modulate alpha-synuclein aggregation and toxicity
Mitochondrial Dysfunction: PD involves complex I deficiency and mitochondrial dysfunction:
- HO-1 protects against mitochondrial oxidative damage
- CO preserves mitochondrial complex activity
- Bilirubin maintains mitochondrial membrane potential
Dopaminergic Neuron Vulnerability: Substantia nigra neurons are particularly susceptible:
- High iron content makes them vulnerable to oxidative stress
- HO-1 induction is particularly prominent in these neurons
- The balance between neuroprotection and iron release is critical
Iron Dysregulation: PD involves regional iron accumulation:
- HO-1 can release iron during heme catabolism
- Chronic HO-1 activity may contribute to iron load
- Ferritin induction may be insufficient to sequester released iron
HO-1-based therapies for PD include:
- Pharmacological inducers: Flavonoids, statins, and nutraceuticals
- Gene therapy: AAV-HO-1 delivery in preclinical models showed promise
- CO-releasing molecules: Low-dose CO may provide neuroprotection
- Combination approaches: HO-1 inducers with antioxidants or anti-inflammatory agents [@takahashi2017]
Amyotrophic lateral sclerosis is a fatal neurodegenerative disorder affecting upper and lower motor neurons. HO-1 is upregulated in ALS:
- Increased expression in spinal cord motor neurons
- Localization to activated astrocytes and microglia
- Correlation with disease progression
- Detection in CSF as a potential biomarker
The induction of HO-1 in ALS represents a cellular stress response to motor neuron injury, protein aggregation, and neuroinflammation. [@kikuchi2022]
Motor Neuron Vulnerability: Motor neurons exhibit specific vulnerabilities:
- High metabolic demand makes them susceptible to oxidative stress
- Protein aggregation triggers cellular stress responses
- HO-1 induction reflects attempts at neuroprotection
Glial Contributions: Astrocytes and microglia contribute to disease progression:
- Dysregulated neuroinflammation in ALS
- Astrocytic HO-1 may influence motor neuron survival
- Microglial HO-1 modulates neuroinflammation
Therapeutic Potential: Strategies to modulate HO-1 in ALS:
- Enhancement of beneficial HO-1 effects
- Prevention of maladaptive chronic activation
- Combination with other neuroprotective approaches
¶ Stroke and Cerebral Ischemia
HO-1 is rapidly induced following cerebral ischemia-reperfusion injury:
- Protective effects in animal models of stroke
- CO-mediated vasodilation improves cerebral blood flow
- Anti-inflammatory actions reduce post-ischemic damage
- HO-1 gene therapy shows promise in preclinical studies [@chang2021]
Following traumatic brain injury, HO-1 is induced as part of the injury response:
- Dual roles: initial protection versus chronic dysregulation
- Therapeutic window for HO-1 modulation
- Potential as a biomarker for injury severity [@wu2021]
HO-1 expression is altered in Huntington's disease:
- Upregulation in affected brain regions
- Relationship to mutant huntingtin toxicity
- Potential therapeutic target
¶ Multiple Sclerosis and Demyelination
In demyelinating diseases, HO-1 is involved in:
- Oligodendrocyte protection
- Myelin repair processes
- Modulation of neuroinflammation
¶ Ferroptosis and HO-1
Recent research has revealed important connections between HO-1 and ferroptosis, a form of regulated cell death characterized by iron-dependent lipid peroxidation:
HO-1 as a Double-Edged Sword:
- Acute HO-1 induction can prevent ferroptosis by reducing labile iron and producing antioxidant biliverdin
- Chronic HO-1 activation can promote ferroptosis through iron release
- The timing and context of HO-1 activation determines its effects
Therapeutic Implications:
- Short-term HO-1 activation may be protective
- Iron chelation combined with HO-1 modulation
- Targeting the balance between protection and iron release [@xinhua2022]
Several classes of compounds can upregulate HO-1 expression:
Natural Products:
- Curcumin: Strong HO-1 inducer via Nrf2 activation
- Sulforaphane: Broccoli-derived Nrf2 activator
- Resveratrol: Sirt1-mediated HO-1 upregulation
- Flavonoids: Wide range of HO-1 inducing activity [@chung2018]
Pharmacological Agents:
- Statins: HMG-CoA reductase inhibitors with HO-1 inducing properties
- Dimethyl fumarate: Approved for MS, activates Nrf2-HO-1 pathway
- Aspirin: Low-dose induces HO-1 in endothelial cells
CO-releasing molecules provide the beneficial effects of HO-1 activity without heme degradation:
- Metal-carbonyl based CORMs
- Light-activated CORMs
- Enzyme-triggered CO release
CO mediates:
- Anti-inflammatory signaling
- Anti-apoptotic effects
- Vasodilation
- Mitochondrial protection [@yoshikawa2020]
Viral vector-mediated HO-1 delivery:
- AAV-based gene therapy shows promise in preclinical models
- Targeted delivery to affected brain regions
- Controlled expression systems
- Combination with other therapeutic genes
¶ Challenges and Considerations
Biphasic Nature of HO-1: The effects of HO-1 are context-dependent:
- Acute induction: Protective
- Chronic dysregulation: Potentially harmful
- Iron release vs. antioxidant protection balance
Cell-Type Specific Effects: HO-1 in different cell types may have distinct effects:
- Neuronal vs. astrocytic vs. microglial HO-1
- Therapeutic targeting must consider cell specificity
Systemic vs. CNS Effects: Peripheral HO-1 induction may have indirect CNS effects:
- Peripheral anti-inflammatory actions
- Modulation of gut-brain axis
- Systemic iron metabolism
Biomarker Potential: HO-1 has potential as:
- Disease progression biomarker
- Therapeutic response indicator
- Diagnostic tool in certain conditions [@caldi2022]
¶ Key Publications and Clinical Evidence
- Schipper HM et al., Heme oxygenase-1 in neurodegenerative disease (2019)
- Piantadosi CA et al., Heme oxygenase-1 and brain injury (2018)
- Song W et al., Heme oxygenase-1 in Alzheimer's disease (2020)
- Takahashi T et al., Heme oxygenase-1 gene therapy for Parkinson's disease (2017)
- Dorazio JL et al., HO-1 upregulation in Parkinson's disease (2021)
- Kikuchi A et al., Heme oxygenase-1 in ALS pathogenesis (2022)
- Chen J et al., Mitochondrial HO-1 in neurodegeneration (2023)
- Chang CF et al., HO-1 mediates neuroprotection in stroke (2021)
- Alam J et al., Nrf2-HO-1 pathway in cellular stress response (2022)
- Goetzl EJ et al., HO-1 polymorphisms and Alzheimer's disease (2020)
- Lin TK et al., Heme oxygenase-1 and Parkinson's disease (2007)
- Chung JY et al., HO-1 induction by flavonoids in neurodegeneration (2018)
- Nath KA et al., Heme oxygenase-2 and the brain (2019)
- Wu L et al., HO-1 in traumatic brain injury (2021)
- Caldi M et al., HO-1 targeting for neurotherapeutics (2022)
- Kim DH et al., Iron metabolism and HO-1 in neurodegeneration (2023)
- Peacock L et al., Astrocyte HO-1 in Alzheimer's disease (2023)
- Schipper HM et al, Heme oxygenase-1 in neurodegenerative disease (2019)
- Piantadosi CA et al, Heme oxygenase-1 and brain injury (2018)
- Song W et al, Heme oxygenase-1 in Alzheimer's disease (2020)
- Takahashi T et al, Heme oxygenase-1 gene therapy for Parkinson's disease (2017)
- Barsoum SB et al, Heme oxygenase-1 and neuroinflammation (2019)
- Dorazio JL et al, HO-1 upregulation in Parkinson's disease (2021)
- Kikuchi A et al, Heme oxygenase-1 in ALS pathogenesis (2022)
- Chen J et al, Mitochondrial HO-1 in neurodegeneration (2023)
- Chang CF et al, HO-1 mediates neuroprotection in stroke (2021)
- Yoshikawa M et al, Carbon monoxide signaling in neurodegeneration (2020)
- Alam J et al, Nrf2-HO-1 pathway in cellular stress response (2022)
- Goetzl EJ et al, HO-1 polymorphisms and Alzheimer's disease (2020)
- Lin TK et al, Heme oxygenase-1 and Parkinson's disease (2007)
- Chung JY et al, HO-1 induction by flavonoids in neurodegeneration (2018)
- Nath KA et al, Heme oxygenase-2 and the brain (2019)
- Wu L et al, HO-1 in traumatic brain injury (2021)
- Caldi M et al, HO-1 targeting for neurotherapeutics (2022)
- Kim DH et al, Iron metabolism and HO-1 in neurodegeneration (2023)
- Schipper HM et al, Heme oxygenase: a novel target for oxidative brain injury (2000)
- Xin Q et al, HO-1 and ferroptosis in neurodegeneration (2022)
- Peacock L et al, Astrocyte HO-1 in Alzheimer's disease (2023)